Skip to content

Study · Non-randomized trial · n = 18 · 1999

4 results

Antimüllerian hormone in patients with hypogonadotropic hypogonadism.

Young J, Rey R, Couzinet B, Chanson P, Josso N, Schaison G

The Journal of clinical endocrinology and metabolism1 Aug 1999Cited by 63 (Europe PMC)

PMID10443662 (opens in a new tab)DOI10.1210/jcem.84.8.5972 (opens in a new tab)PepBankPUB-10443662
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with hypogonadotropic hypogonadism, hCG was followed by a larger fall in serum AMH than exogenous testosterone, despite similar rises in plasma testosterone.

    In plain wordsIn patients with hypogonadotropic hypogonadism, hCG lowered AMH more than exogenous testosterone did, although testosterone rose by a similar amount.

    Peptide
    hCG (human chorionic gonadotropin)
    Outcome
    DecreaseAMH decrease versus exogenous testosterone
    Study

    n = 18

    Comparator
    Exogenous testosterone
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1500 IU/twice weekly · 6 monthsAs given in this study (human).

    Measurements

    Serum AMH
    314 pmol/L
    hCG group, baseline
    Serum AMH
    56 pmol/L
    hCG group, 3 months
    Serum AMH
    17 pmol/L
    hCG group, 6 months
    Serum AMH
    221 pmol/L
    exogenous testosterone group, baseline
    Serum AMH
    114 pmol/L
    exogenous testosterone group, 3 months
    Serum AMH
    66 pmol/L
    exogenous testosterone group, 6 months
    Serum AMH reported +/- uncertainty
    93 pmol/L
    hCG group, baseline, parent value 314 pmol/L, uncertainty type not stated in summary
    Serum AMH reported +/- uncertainty
    30 pmol/L
    hCG group, 3 months, parent value 56 pmol/L, uncertainty type not stated in summary

    4 more measurements in the study.

    Source sentences

    Summary
    hCG treatment induced an increase of plasma T (from 1.0+/-0.7 to 11+/-2.4 and 19+/-4.8 nmol/L, at 3 and 6 months respectively) associated with a dramatic decrease of serum AMH (from 314+/-93 to 56+/-30 and 17+/-4.3 pmol/L).
    Summary
    The similar increase in plasma T levels (from 1.4+/-1.0 to 15.6+/-4.2 and 23+/-6.2 ng/mL) obtained with exogenous T induced a lesser decrease of serum AMH (from 221+/-107 pmol/L to 114+/-50 and 66+/-17 pmol/L, at 3 and 6 months respectively).
  2. 02HumanNon-randomized trialEfficacy outcome

    In HH patients, hCG increased plasma testosterone from 1.0 to 11 and 19 nmol/L at 3 and 6 months respectively.

    In plain wordsIn HH patients, hCG increased plasma testosterone at 3 and 6 months compared with baseline.

    Peptide
    hCG (human chorionic gonadotropin)
    Outcome
    IncreasePlasma testosterone
    Study

    n = 10

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1500 IU/twice weekly · 6 monthsAs given in this study (human).

    Measurements

    Plasma testosterone
    1 nmol/L
    baseline, mean +/- SD 0.7
    Plasma testosterone
    11 nmol/L
    3 months of hCG, mean +/- SD 2.4
    Plasma testosterone
    19 nmol/L
    6 months of hCG, mean +/- SD 4.8
    Plasma testosterone reported +/- uncertainty
    0.7 nmol/L
    hCG group, baseline, parent value 1.0 nmol/L, uncertainty type not stated in summary
    Plasma testosterone reported +/- uncertainty
    2.4 nmol/L
    hCG group, 3 months, parent value 11 nmol/L, uncertainty type not stated in summary
    Plasma testosterone reported +/- uncertainty
    4.8 nmol/L
    hCG group, 6 months, parent value 19 nmol/L, uncertainty type not stated in summary

    Source sentences

    Summary
    hCG treatment induced an increase of plasma T (from 1.0+/-0.7 to 11+/-2.4 and 19+/-4.8 nmol/L, at 3 and 6 months respectively) associated with a dramatic decrease of serum AMH (from 314+/-93 to 56+/-30 and 17+/-4.3 pmol/L).
    1 context sentence
    Summary · context
    Plasma testosterone (T) and serum AMH levels were measured at baseline and at 3 and 6 months in 10 HH patients (6 CHH and 4 AHH) treated with hCG (1500 IU/twice weekly for 6 months)
  3. 03HumanNon-randomized trialEfficacy outcome

    In HH patients, hCG decreased serum AMH from 314 to 56 and 17 pmol/L alongside increased testosterone.

    In plain wordsIn HH patients, hCG decreased serum AMH compared with baseline alongside increased testosterone.

    Peptide
    hCG (human chorionic gonadotropin)
    Outcome
    DecreaseSerum AMH
    Study

    n = 10

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1500 IU/twice weekly · 6 monthsAs given in this study (human).

    Measurements

    Serum AMH
    314 pmol/L
    baseline, mean +/- SD 93
    Serum AMH
    56 pmol/L
    3 months of hCG, mean +/- SD 30
    Serum AMH
    17 pmol/L
    6 months of hCG, mean +/- SD 4.3
    Serum AMH reported +/- uncertainty
    93 pmol/L
    hCG group, baseline, parent value 314 pmol/L, uncertainty type not stated in summary
    Serum AMH reported +/- uncertainty
    30 pmol/L
    hCG group, 3 months, parent value 56 pmol/L, uncertainty type not stated in summary
    Serum AMH reported +/- uncertainty
    4.3 pmol/L
    hCG group, 6 months, parent value 17 pmol/L, uncertainty type not stated in summary

    Source sentences

    Summary
    hCG treatment induced an increase of plasma T (from 1.0+/-0.7 to 11+/-2.4 and 19+/-4.8 nmol/L, at 3 and 6 months respectively) associated with a dramatic decrease of serum AMH (from 314+/-93 to 56+/-30 and 17+/-4.3 pmol/L).
    1 context sentence
    Summary · context
    Plasma testosterone (T) and serum AMH levels were measured at baseline and at 3 and 6 months in 10 HH patients (6 CHH and 4 AHH) treated with hCG (1500 IU/twice weekly for 6 months)
  4. 04HumanObservational studyMechanism

    In patients treated for prostate cancer, serum AMH increased from 11.4 to 49 pmol/L after 12 months of triptorelin.

    In plain wordsIn patients treated for prostate cancer, AMH increased after 12 months of triptorelin compared with baseline.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseSerum antimullerian hormone
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg once a month · IM · 12 monthsAs given in this study (human).

    Measurements

    Serum AMH
    11.4 pmol/L
    baseline
    Serum AMH
    49 pmol/L
    12 months after gonadal axis suppression with triptorelin
    P value
    < 0.01
    change from baseline

    Source sentences

    Summary
    In addition, in 10 patients treated for prostate cancer, a modest but significant increase of serum AMH (from 11.4 +/-5.7 pmol/L to 49+/-9.9 pmol/L; P < 0.01) was observed 12 months after suppression of the gonadal axis with the GnRH agonist Triptorelin (3.75 mg IM once a month).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    14 Oct 2026, 05:02 UTC

    Study results updated

  3. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.